ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 775

Cutaneous Gene Expression Signatures in Juvenile Myositis Reveal a Prominent IFN Signature in Lesional Skin

Jessica Turnier1, Celine Berthier 1, Lam Tsoi 1, Lori Lowe 1, Gabrielle Morgan 2, Johann Gudjonsson 1, Lauren Pachman 2 and J. Michelle Kahlenberg 1, 1University of Michigan, Ann Arbor, MI, 2Northwestern University, Chicago

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Autoimmune Skin Disease, childhood-onset lupus, interferons and bioinformatics, juvenile myositis

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 10, 2019

Title: Pediatric Rheumatology – ePoster I: Basic Science, Biomarkers, & Sclerodermic Fever

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Skin inflammation can herald systemic disease manifestations and disease chronicity in juvenile myositis (JM), yet we lack an understanding of the pathogenic mechanisms driving skin inflammation in JM. The objectives of this study were to 1) define transcriptional signatures and biological networks in JM lesional skin, and 2) identify key genes and pathways that differentiate skin disease in JM from childhood-onset SLE (cSLE).       

Methods: With IRB approval, we identified JM and cSLE patients who had a skin biopsy performed at either the University of Michigan or Lurie Children’s Hospital of Chicago and verified diagnosis through chart review of clinical findings, labs, imaging and histopathology. We then isolated RNA from formalin-fixed, paraffin-embedded (FFPE) skin biopsy samples of 15 JM (9 lesional, 6 non-lesional), 7 cSLE and 8 control patients (CTL; samples from uninvolved skin removed with nevi excision). Following RNA isolation, we performed microarray analysis using Affymetrix ST 2.1 arrays and significance analysis of microarrays (SAM) to determine differentially expressed genes (DEGs; q-value ≤ 5%) between patient groups, comparing JM lesional (JM_L), JM non-lesional (JM_NL), cSLE and CTL. We utilized Ingenuity Pathway Analysis (IPA) to highlight enriched biological pathways and Genomatix Pathway System (GePS) to characterize regulated genes within biological networks.

Results: In the JM cohort, 2 patients had amyopathic disease, and 2 lacked characteristic skin findings of Gottron’s papules, with the remaining patients having a classical JDM presentation. Principal component analysis demonstrated that the 2 patients without characteristic skin findings of JDM clustered with other JM_L patients. Comparison of JM_L to CTL skin revealed 221 DEGs, with all but one upregulated in JM_L. The majority of upregulated genes in JM_L were IFN-sensitive, with CXCL10, CXCL9 and IFI44L representing the top three DEGs (FC = 23.2, 13.3, 13.0, q-value = < 0.0001) (Figure 1). IPA revealed IFN signaling as the top canonical pathway and also showed upregulation of antigen presentation, pattern recognition receptors, communication between innate and adaptive immune cells, T cell signaling, the complement system and dendritic cell maturation. The top predicted upstream regulator was IFN alpha (p-value = 7.91×10-88). JM_NL skin had a strikingly different transcriptional signature, both lacking a prominent IFN signal and with downregulation of multiple genes and pathways, including oxidative phosphorylation and protein ubiquitination. JM_L skin shared a highly similar gene expression pattern with cSLE. There were only 28 unique DEGs in JM_L compared to cSLE, whereas cSLE skin had 722 unique DEGs compared to JM_L. Of note, cSLE skin uniquely demonstrated increased expression of IFN gamma relative to CTL.

Conclusion: JM lesional skin demonstrates a striking IFN signature similar to that previously reported in muscle and peripheral blood. Although JM skin has few unique DEGs when compared to cSLE, a lack of upregulated genes specific to cSLE skin may distinguish JM. The origin of the IFN signature in JM skin and its association with clinical phenotype and response to therapy remains to be established.


Heatmap for JDM_ACR abstract_FINAL

Figure 1. Top three differentially expressed genes in JM lesional skin compared to control and JM non-lesional skin


Disclosure: J. Turnier, None; C. Berthier, None; L. Tsoi, None; L. Lowe, None; G. Morgan, None; J. Gudjonsson, AbbVie, 2, Genentech, 2, genentech, 2, MiRagen, 5, Novartis, 5, Sun Pharma, 2, SunPharma, 2; L. Pachman, Reveragen, 2, SBIR grant Eric P. Hofffman, PhD RevaraGen, unrelated.,, 9; J. Kahlenberg, AstraZeneca, Eli Lilly, Bristol Myers Squibb.

To cite this abstract in AMA style:

Turnier J, Berthier C, Tsoi L, Lowe L, Morgan G, Gudjonsson J, Pachman L, Kahlenberg J. Cutaneous Gene Expression Signatures in Juvenile Myositis Reveal a Prominent IFN Signature in Lesional Skin [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/cutaneous-gene-expression-signatures-in-juvenile-myositis-reveal-a-prominent-ifn-signature-in-lesional-skin/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cutaneous-gene-expression-signatures-in-juvenile-myositis-reveal-a-prominent-ifn-signature-in-lesional-skin/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology